FSD Pharma Inc Class B Company Overview
FSD Pharma Inc Class B
About FSD Pharma Inc Class B
FSD Pharma Inc. Class B (NASDAQ:HUGE) is focused on developing innovative therapies for the treatment of inflammatory diseases. The company is involved in cutting-edge pharmaceutical research, aiming to bring efficient and cost-effective drugs to market. One of its primary projects is Lucid-MS, a treatment for multiple sclerosis. FSD's goal is to leverage its research capabilities and pharmaceutical expertise to address unmet medical needs and improve patient outcomes.
What is FSD Pharma Inc Class B known for?
Snapshot
2008
Year founded
0
Employees
Toronto, Canada
Head office
Loading Map...
Operations
All Locations
Toronto, CA
Produtos e/ou serviços de FSD Pharma Inc Class B
- Phase 2 clinical trial of FSD201 for the treatment of COVID-19, aimed at addressing inflammatory disorders.
- Psychedelics R&D aimed at exploring novel treatments for mental health disorders, including depression and PTSD.
- Cannabinoid-based pharmaceuticals research focusing on innovative treatments for pain management and other inflammatory conditions.
- Strategic collaboration with other biotech firms to co-develop groundbreaking therapies for various diseases.
- Acquisition and investment in biotech companies to expand research and development capabilities.
- Development of ultramicro PEA molecules targeting chronic inflammatory diseases, promoting advanced therapeutic solutions.
equipe executiva do FSD Pharma Inc Class B
- Mr. Zeeshan SaeedFounder, CEO, President & Executive Co-Chairman
- Mr. Anthony John DurkaczFounder & Executive Co-Chairman
- Mr. Nathan Coyle CPAChief Financial Officer
- Mr. Donal Carroll CPAChief Operating Officer
- Dr. Lakshmi P. Kotra BPHARM, Ph.D.CEO of Lucid & Director
- Ms. Maryann AdessoCorporate Secretary
- Randell MackPresident of FSD BioSciences
- Dr. Andrzej Chruscinski M.D., Ph.D.Vice President of Clinical & Scientific Affairs of Lucid
- Mr. Kevin CassidyVice President of Quality-Lucid